Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy

Background The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. Methods A total of 234 SCLC patients, who received first‐line platinum‐based...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Man He, Xiaorui Chi, Xinyan Shi, Yang Sun, Xue Yang, Leirong Wang, Bingrui Wang, Hongmei Li
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	LDH OS prognosis SCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/47ae4f268c6a44c288667897141c8b59
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:47ae4f268c6a44c288667897141c8b59
record_format	dspace
spelling	oai:doaj.org-article:47ae4f268c6a44c288667897141c8b592021-12-02T02:34:55ZValue of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy1759-77141759-770610.1111/1759-7714.13581https://doaj.org/article/47ae4f268c6a44c288667897141c8b592021-12-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.13581https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Background The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. Methods A total of 234 SCLC patients, who received first‐line platinum‐based chemotherapy between 2013 and 2018, were retrospectively analyzed. The data of hematological characteristics, age, gender, ECOG score, staging, metastatic site, smoking history, chemotherapy cycle, thoracic radiotherapy and hyponatremia were collected. Overall survival was calculated using the Kaplan‐Meier method. The statistically significant factors in the univariate analysis were selected for the multivariate COX model analysis. Results Age, ECOG score, stage, thoracic radiotherapy, hyponatremia, liver metastasis, brain metastasis, bone metastasis, LDH, NSE and neutrophil‐to‐lymphocyte ratio (NLR) were closely correlated to OS in the univariate analysis. Furthermore, the multivariate analysis revealed that age (<65 years), ECOG score (<2 points), limited‐stage (LD), thoracic radiotherapy and LDH <215.70 U/L were the independent prognostic factors for survival. The median OS time was worse for patients with LDH ≥215.70 U/L. In the subgroup analysis, LDH ≥215.70 U/L was significant for survival in both limited and extensive disease. Patients who achieved CR + PR in the first‐line treatment had lower initial LDH levels. It was found that the pretreatment LDH increased the incidence of patients with liver metastasis. Conclusions Positive independent prognostic factors for SCLC patients were age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L. These factors may be useful for stratifying patients with SCLC for treatment approaches. Key points Significant findings of the study Age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L are the positive independent prognostic factors for SCLC patients. What this study adds The current study provided more references for SCLC diagnosis and treatment and determined more factors for stratifying patients with SCLC for treatment approaches.Man HeXiaorui ChiXinyan ShiYang SunXue YangLeirong WangBingrui WangHongmei LiWileyarticleLDHOSprognosisSCLCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 23, Pp 3101-3109 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	LDH OS prognosis SCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	LDH OS prognosis SCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Man He Xiaorui Chi Xinyan Shi Yang Sun Xue Yang Leirong Wang Bingrui Wang Hongmei Li Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
description	Background The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. Methods A total of 234 SCLC patients, who received first‐line platinum‐based chemotherapy between 2013 and 2018, were retrospectively analyzed. The data of hematological characteristics, age, gender, ECOG score, staging, metastatic site, smoking history, chemotherapy cycle, thoracic radiotherapy and hyponatremia were collected. Overall survival was calculated using the Kaplan‐Meier method. The statistically significant factors in the univariate analysis were selected for the multivariate COX model analysis. Results Age, ECOG score, stage, thoracic radiotherapy, hyponatremia, liver metastasis, brain metastasis, bone metastasis, LDH, NSE and neutrophil‐to‐lymphocyte ratio (NLR) were closely correlated to OS in the univariate analysis. Furthermore, the multivariate analysis revealed that age (<65 years), ECOG score (<2 points), limited‐stage (LD), thoracic radiotherapy and LDH <215.70 U/L were the independent prognostic factors for survival. The median OS time was worse for patients with LDH ≥215.70 U/L. In the subgroup analysis, LDH ≥215.70 U/L was significant for survival in both limited and extensive disease. Patients who achieved CR + PR in the first‐line treatment had lower initial LDH levels. It was found that the pretreatment LDH increased the incidence of patients with liver metastasis. Conclusions Positive independent prognostic factors for SCLC patients were age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L. These factors may be useful for stratifying patients with SCLC for treatment approaches. Key points Significant findings of the study Age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L are the positive independent prognostic factors for SCLC patients. What this study adds The current study provided more references for SCLC diagnosis and treatment and determined more factors for stratifying patients with SCLC for treatment approaches.
format	article
author	Man He Xiaorui Chi Xinyan Shi Yang Sun Xue Yang Leirong Wang Bingrui Wang Hongmei Li
author_facet	Man He Xiaorui Chi Xinyan Shi Yang Sun Xue Yang Leirong Wang Bingrui Wang Hongmei Li
author_sort	Man He
title	Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_short	Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_full	Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_fullStr	Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_full_unstemmed	Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_sort	value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/47ae4f268c6a44c288667897141c8b59
work_keys_str_mv	AT manhe valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy AT xiaoruichi valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy AT xinyanshi valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy AT yangsun valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy AT xueyang valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy AT leirongwang valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy AT bingruiwang valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy AT hongmeili valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
_version_	1718402346977853440

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy

Ejemplares similares